ELAN - Elanco Animal Health Incorporated
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Greenfield,
United States
Type: Equity
ELAN price evolution
ELAN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $416 | $345 | $352 | |
| Short term investments | ||||
| Net receivables | $904 | $1080 | $1078 | $1010 |
| Inventory | $1632 | $1611 | $1638 | $1735 |
| Total current assets | $3366 | $4011 | $4050 | $3407 |
| Long term investments | ||||
| Property, plant & equipment | $979 | $949 | $949 | $1026 |
| Goodwill & intangible assets | $8480 | $8674 | $9588 | |
| Total noncurrent assets | $9753 | $9969 | $10955 | |
| Total investments | ||||
| Total assets | $13283 | $13764 | $14019 | $14362 |
| Current liabilities | ||||
| Accounts payable | $259 | $291 | $302 | $270 |
| Deferred revenue | ||||
| Short long term debt | $213 | $38 | $38 | |
| Total current liabilities | $1321 | $1370 | $1232 | $1241 |
| Long term debt | $4313 | $5463 | $5727 | $5736 |
| Total noncurrent liabilities | $6452 | $6731 | $6898 | |
| Total debt | $5676 | $5765 | $5774 | |
| Total liabilities | $6760 | $7822 | $7963 | $8139 |
| Shareholders' equity | ||||
| Retained earnings | -$1942 | -$2306 | -$2256 | -$2288 |
| Other shareholder equity | -$339 | -$542 | -$465 | -$266 |
| Total shareholder equity | $5942 | $6056 | $6223 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $352 | $345 | $638 | $505.4 |
| Short term investments | ||||
| Net receivables | $1010 | $1002 | $1028 | $1076.7 |
| Inventory | $1735 | $1538 | $1373 | $1578.1 |
| Total current assets | $3407 | $3279 | $3276 | $3416.5 |
| Long term investments | $33.4 | |||
| Property, plant & equipment | $1026 | $1140 | $1061 | $1316.3 |
| Goodwill & intangible assets | $9588 | $10835 | $11759 | $12612.1 |
| Total noncurrent assets | $10955 | $12212 | $13207 | $14276.2 |
| Total investments | ||||
| Total assets | $14362 | $15491 | $16483 | $17692.7 |
| Current liabilities | ||||
| Accounts payable | $270 | $390 | $418 | $506 |
| Deferred revenue | ||||
| Short long term debt | $38 | $388 | $294 | $554.5 |
| Total current liabilities | $1241 | $1702 | $1643 | $2076.3 |
| Long term debt | $5736 | $5448 | $6025 | $5572.4 |
| Total noncurrent liabilities | $6898 | $6500 | $7302 | $7140.5 |
| Total debt | $5774 | $5836 | $6319 | $6126.9 |
| Total liabilities | $8139 | $8202 | $8945 | $9216.8 |
| Shareholders' equity | ||||
| Retained earnings | -$2288 | -$1057 | -$949 | -$477.2 |
| Other shareholder equity | -$266 | -$392 | -$209 | $303 |
| Total shareholder equity | $6223 | $7289 | $7538 | $8475.9 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1184 | $1205 | $1035 | |
| Cost of revenue | $495 | $515 | $516 | |
| Gross Profit | $689 | $690 | $519 | |
| Operating activities | ||||
| Research & development | $89 | $87 | $79 | |
| Selling, general & administrative | $354 | $337 | $292 | |
| Total operating expenses | $656 | $612 | $579 | |
| Operating income | $33 | $78 | -$60 | |
| Income from continuing operations | ||||
| EBIT | $33 | $78 | -$60 | |
| Income tax expense | $18 | -$20 | $14 | |
| Interest expense | $65 | $66 | $67 | |
| Net income | ||||
| Net income | -$50 | $32 | -$141 | |
| Income (for common shares) | -$50 | $32 | -$141 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4417 | $4411 | $4765 | $3273.3 |
| Cost of revenue | $1931 | $1913 | $2134 | $1666.6 |
| Gross Profit | $2486 | $2498 | $2631 | $1606.7 |
| Operating activities | ||||
| Research & development | $327 | $321 | $369 | $327 |
| Selling, general & administrative | $1285 | $1265 | $1404 | $996.6 |
| Total operating expenses | $3404 | $2329 | $2962 | $2128.9 |
| Operating income | -$918 | $169 | -$331 | -$522.2 |
| Income from continuing operations | ||||
| EBIT | -$918 | $169 | -$331 | -$522.2 |
| Income tax expense | $36 | $6 | -$95 | -$111.9 |
| Interest expense | $277 | $241 | $236 | $149.8 |
| Net income | ||||
| Net income | -$1231 | -$78 | -$472 | -$560.1 |
| Income (for common shares) | -$1231 | -$78 | -$472 | -$560.1 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$50 | $32 | -$141 | |
| Operating activities | ||||
| Depreciation | $162 | $166 | $171 | |
| Business acquisitions & disposals | -$5 | |||
| Stock-based compensation | $14 | $11 | $15 | |
| Total cash flows from operations | $200 | $2 | $157 | |
| Investing activities | ||||
| Capital expenditures | -$34 | $42 | -$41 | |
| Investments | ||||
| Total cash flows from investing | $1248 | -$33 | $37 | -$35 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$92 | -$13 | -$139 | |
| Total cash flows from financing | -$1460 | -$93 | -$27 | -$139 |
| Effect of exchange rate | -$14 | -$3 | -$19 | |
| Change in cash and equivalents | $138 | $71 | -$7 | -$17 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$1231 | -$78 | -$472 | -$560.1 |
| Operating activities | ||||
| Depreciation | $694 | $682 | $716 | $516.9 |
| Business acquisitions & disposals | -$19 | $13 | -$342 | -$4566.6 |
| Stock-based compensation | $46 | $59 | $66 | $47.7 |
| Total cash flows from operations | $271 | $452 | $483 | -$41 |
| Investing activities | ||||
| Capital expenditures | -$140 | -$171 | -$142 | -$238.2 |
| Investments | $32.7 | |||
| Total cash flows from investing | -$169 | -$179 | -$530 | -$4779.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1219.9 | |||
| Net borrowings | -$77 | -$533 | $239 | $3750.2 |
| Total cash flows from financing | -$83 | -$549 | $210 | $4953.9 |
| Effect of exchange rate | -$12 | -$17 | -$31 | $26.6 |
| Change in cash and equivalents | $7 | -$293 | $132 | $160.3 |
News
Fundamentals
| Market cap | $12.13B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 494.33M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.31 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.55 |
| Quick ratio | 1.31 |